More bad vibes kill off Merck’s TIGIT and Lag3
Merck ditches vibostolimab and favezelimab following huge pivotal programmes.
Bicycle has a wobble
Zelenectide looks uncompetitive versus Padcev in bladder cancer, while elsewhere a biomarker strategy beckons.
SABCS 2024 – Lilly's PI3Kα push is no longer mutation-specific
Lilly sheds more light on its second PI3Kα take, as Relay's combo data improve.
ASH 2024 movers – moments of reckoning for menin and BTK
Menin, BTK and a Car-T skirmish featured over the ASH weekend.
Candel will need more than a Christmas miracle
The company impresses investors, but money’s running short.
SABCS 2024 – Ember-3 dims hopes for Lilly’s SERD
Imlunestrant monotherapy only works in ESR1 mutants, but a Verzenio combo is better in all-comers.
ASH 2024 – Arcellx is happy to share in Car-T
Much has been made of anito-cel’s rivalry with Carvykti, but Arcellx reckons there’s plenty of market for both.
ASH 2024 – Astra sets the bar for Merck's Curon buy
AZD0486 seems highly active, including in patients relapsed on Car-T therapy.
